Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2010-09-15 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Second Successful PRRS VaccineTrial 4 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene reporting successful results from a second US trial of their PRRS vaccine for pigs. It details trial results, efficacy data, and commercial implications. The content is focused on announcing clinical trial outcomes and product development progress rather than providing comprehensive financial data, regulatory filings, or management commentary. It is not a full financial report, audit report, earnings release, or investor presentation. The document is a corporate announcement about a scientific trial result, which fits best under a general regulatory announcement category. There is no indication that this is a report publication announcement or a certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2010-09-15 English
Preliminary Final Report 11 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary final report Year ended 30 June 2010' and contains detailed financial statements including consolidated statement of comprehensive income, statement of financial position, statement of cash flows, and notes to these statements. It covers a full fiscal year ending 30 June 2010 and includes comparative figures for the prior year. The report mentions it is based on accounts in the process of being audited, which is typical for preliminary final reports. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are essentially annual reports but preliminary and not the full audited annual report (10-K equivalent). The document is 15,000 characters long, indicating it is a substantive financial report, not just an announcement or certification. Therefore, this document is best classified as an Interim / Quarterly Report (IR) because Appendix 4E is a preliminary final report, which is a comprehensive financial report for the year but preliminary and not the full annual report. It is not a full Annual Report (10-K) because it is preliminary and states accounts are still being audited. It is not a simple announcement or certification, so RPA or RNS is not appropriate. FY 2010
2010-08-30 English
Quarterly Report and Appendix 4C 6 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update' and includes detailed financial data for the quarter ended 30 June 2010, including cash flow statements, payments to directors, reconciliation of cash, and compliance statements. It also references Appendix 4C, which is a recognized quarterly report format for entities admitted on the basis of commitments, commonly used in Australian stock exchange filings. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2010
2010-07-29 English
Shareholder Update Commercial Negotiations 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Shareholder Update' dated 2 July 2010. It discusses ongoing commercial licensing negotiations, due diligence with a preferred partner, and updates on vaccine trials. The content is a progress update to shareholders rather than a full financial report or detailed earnings release. The document length is 3728 characters, which is relatively short and consistent with an announcement rather than a comprehensive report. There is no detailed financial data, no regulatory certifications, or formal voting results. The document is clearly an update to shareholders about business developments and negotiations, fitting the category of Capital/Financing Update (CAP) as it relates to commercial licensing and partnership negotiations impacting the company's capital and business prospects.
2010-07-01 English
Quarterly Update and Appendix 4C 6 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update' and includes detailed financial data such as cash flows, payments to directors, and reconciliation of cash for the quarter ended 31 March 2010. It also contains an Appendix 4C, which is a quarterly report format used by entities admitted on the basis of commitments, commonly seen in Australian stock exchange filings. The document is over 11,000 characters, indicating it is a substantive report rather than a brief announcement. The content includes actual financial statements and analysis for a period shorter than a full fiscal year (quarterly). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2010
2010-04-29 English
Investor Update 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 7 April 2010 titled 'Investor Update'. It provides progress information on licensing discussions and development programs for Imugene's vaccines. The content focuses on business updates and ongoing negotiations rather than financial results or detailed financial statements. The document length is 4060 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial statements, audit information, or regulatory certifications. The document is clearly an update to investors about business progress and licensing activities, fitting the category of Capital/Financing Update (CAP) as it relates to commercial agreements and licensing negotiations, which are financing-related activities. Therefore, the appropriate classification is CAP with high confidence.
2010-04-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.